Novo Nordisk (NVO) Stock Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NVO Analyst Ratings

Hold

1 Buy

11 Hold

2 Sell

Based on 14 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NVO Stock 12 Month Forecast

Average Price Target

zł171.57

▲(1.70% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is zł171.57 with a high forecast of zł201.88 and a low forecast of zł115.36. The average price target represents a 1.70% change from the last price of zł168.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"114":"zł114","136":"zł136","158":"zł158","180":"zł180","202":"zł202"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":201.876647,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">zł201.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":171.57296570307687,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">zł171.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115.358084,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">zł115.36</span>\n  </div></div>","useHTML":true}}],"tickPositions":[114,136,158,180,202],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,179.517,181.23697284615383,182.9569456923077,184.67691853846154,186.39689138461537,188.11686423076924,189.83683707692308,191.5568099230769,193.27678276923075,194.99675561538461,196.71672846153845,198.4367013076923,200.15667415384615,{"y":201.876647,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,179.517,178.90592043869822,178.29484087739644,177.68376131609466,177.07268175479288,176.4616021934911,175.85052263218932,175.23944307088755,174.62836350958577,174.017283948284,173.4062043869822,172.79512482568043,172.18404526437865,{"y":171.57296570307687,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,179.517,174.58169876923077,169.64639753846154,164.71109630769232,159.7757950769231,154.84049384615383,149.9051926153846,144.96989138461538,140.03459015384615,135.09928892307693,130.1639876923077,125.22868646153846,120.29338523076923,{"y":115.358084,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":168.997,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":201.189,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":197.516,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.031,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170.071,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.771,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":200.616,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.367,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.28,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":153.054,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":162.928,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":179.715,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":179.517,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetzł201.88

Average Price Targetzł171.57

Lowest Price Targetzł115.36

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Emmanuel Papadakis

Deutsche Bank

zł167.27→zł152.85

Sell

-9.40%

Downside

Downgraded

08/27/26

Novo Nordisk (0QIU) was downgraded to a Sell Rating at Deutsche Bank

Nico Chen

DBS

zł173.04

Hold

2.57%

Upside

Reiterated

08/25/26

DBS Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Richard Vosser

J.P. Morgan

zł144.2→zł158.62

Hold

-5.98%

Downside

Reiterated

08/25/26

J.P. Morgan Sticks to Its Hold Rating for Novo Nordisk (0QIU)

Kerry Holford

Berenberg Bank

zł187.46→zł175.92

Hold

4.28%

Upside

Downgraded

08/12/26

Novo Nordisk (0QIU) was downgraded to a Hold Rating at Berenberg Bank

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These NA Companies: Novo Nordisk (LSE: GB:0QIU), Symrise (LSE: GB:0G6T) and Fraport AG Frankfurt Airport Services Worldwide (LSE: GB:0O1R)

Graham Parry

Citi

zł190.34→zł178.81

Hold

5.99%

Upside

Reiterated

08/07/26

Novo Nordisk price target lowered to DKK 310 from DKK 330 at CitiNovo Nordisk price target lowered to DKK 310 from DKK 330 at Citi

James Gordon CFA

Barclays

zł173.04→zł178.81

Hold

5.99%

Upside

Reiterated

08/06/26

Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)

Sachin Jain

Bank of America Securities

zł201.88

Hold

19.67%

Upside

Reiterated

08/06/26

Bank of America Securities Sticks to Its Hold Rating for Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

zł178.81→zł164.39

Hold

-2.56%

Downside

Reiterated

08/06/26

Novo Nordisk (0QIU) Gets a Hold from Goldman Sachs

Matthew Weston

UBS

zł191.49

Hold

13.51%

Upside

Reiterated

08/05/26

UBS Keeps Their Hold Rating on Novo Nordisk (0QIU)

Justin Smith

Bernstein

zł115.36

Sell

-31.62%

Downside

Reiterated

08/05/26

Bernstein Reaffirms Their Sell Rating on Novo Nordisk (0QIU)

Michael Leuchten

Jefferies

zł164.39

Hold

-2.56%

Downside

Reiterated

08/04/26

Novo Nordisk (0QIU) Receives a Hold from Jefferies

Rajesh Kumar

HSBC

zł161.5→zł173.04

Hold

2.57%

Upside

Reiterated

07/06/26

Novo Nordisk price target raised to DKK 300 from DKK 280 at HSBCNovo Nordisk price target raised to DKK 300 from DKK 280 at HSBC

Martin Brenoe

Nordea Markets

zł201.88

Buy

19.67%

Upside

Upgraded

06/19/26

Novo Nordisk upgraded to Buy from Hold at NordeaNovo Nordisk upgraded to Buy from Hold at Nordea

David Evans

Kepler Capital

zł161.5→zł167.27

Hold

-0.85%

Downside

Reiterated

05/22/26

Kepler Capital Keeps Their Hold Rating on Novo Nordisk (0QIU)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Emmanuel Papadakis

Deutsche Bank

zł167.27→zł152.85

Sell

-9.40%

Downside

Downgraded

08/27/26

Novo Nordisk (0QIU) was downgraded to a Sell Rating at Deutsche Bank

Nico Chen

DBS

zł173.04

Hold

2.57%

Upside

Reiterated

08/25/26

DBS Reaffirms Their Hold Rating on Novo Nordisk (0QIU)

Richard Vosser

J.P. Morgan

zł144.2→zł158.62

Hold

-5.98%

Downside

Reiterated

08/25/26

J.P. Morgan Sticks to Its Hold Rating for Novo Nordisk (0QIU)

Kerry Holford

Berenberg Bank

zł187.46→zł175.92

Hold

4.28%

Upside

Downgraded

08/12/26

Novo Nordisk (0QIU) was downgraded to a Hold Rating at Berenberg Bank

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

08/07/26

Analysts Have Conflicting Sentiments on These NA Companies: Novo Nordisk (LSE: GB:0QIU), Symrise (LSE: GB:0G6T) and Fraport AG Frankfurt Airport Services Worldwide (LSE: GB:0O1R)

Graham Parry

Citi

zł190.34→zł178.81

Hold

5.99%

Upside

Reiterated

08/07/26

Novo Nordisk price target lowered to DKK 310 from DKK 330 at CitiNovo Nordisk price target lowered to DKK 310 from DKK 330 at Citi

James Gordon CFA

Barclays

zł173.04→zł178.81

Hold

5.99%

Upside

Reiterated

08/06/26

Barclays Keeps Their Hold Rating on Novo Nordisk (0QIU)

Sachin Jain

Bank of America Securities

zł201.88

Hold

19.67%

Upside

Reiterated

08/06/26

Bank of America Securities Sticks to Its Hold Rating for Novo Nordisk (0QIU)

James Quigley

Goldman Sachs

zł178.81→zł164.39

Hold

-2.56%

Downside

Reiterated

08/06/26

Novo Nordisk (0QIU) Gets a Hold from Goldman Sachs

Matthew Weston

UBS

zł191.49

Hold

13.51%

Upside

Reiterated

08/05/26

UBS Keeps Their Hold Rating on Novo Nordisk (0QIU)

Justin Smith

Bernstein

zł115.36

Sell

-31.62%

Downside

Reiterated

08/05/26

Bernstein Reaffirms Their Sell Rating on Novo Nordisk (0QIU)

Michael Leuchten

Jefferies

zł164.39

Hold

-2.56%

Downside

Reiterated

08/04/26

Novo Nordisk (0QIU) Receives a Hold from Jefferies

Rajesh Kumar

HSBC

zł161.5→zł173.04

Hold

2.57%

Upside

Reiterated

07/06/26

Novo Nordisk price target raised to DKK 300 from DKK 280 at HSBCNovo Nordisk price target raised to DKK 300 from DKK 280 at HSBC

Martin Brenoe

Nordea Markets

zł201.88

Buy

19.67%

Upside

Upgraded

06/19/26

Novo Nordisk upgraded to Buy from Hold at NordeaNovo Nordisk upgraded to Buy from Hold at Nordea

David Evans

Kepler Capital

zł161.5→zł167.27

Hold

-0.85%

Downside

Reiterated

05/22/26

Kepler Capital Keeps Their Hold Rating on Novo Nordisk (0QIU)

Stocks with the Highest Top Analyst Consensus in the General Sector

STDNStandard Nuclear

SKHYSK Hynix

ITGITG Inc. Class A

LIMENeutron Holdings, Inc.

EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Novo Nordisk

3 Months

Emmanuel PapadakisDeutsche Bank

Success Rate

38/65 ratings generated profit

Average Return

+1.54%

Copying Emmanuel Papadakis's trades and holding each position for 3 Months would result in 58.46% of your transactions generating a profit, with an average return of +1.54% per trade.

1 Year

Emmanuel PapadakisDeutsche Bank

Success Rate

36/65 ratings generated profit

Average Return

+8.14%

Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 55.38% of your transactions generating a profit, with an average return of +8.14% per trade.

2 Years

Emmanuel PapadakisDeutsche Bank

Success Rate

28/65 ratings generated profit

Average Return

+11.34%

Copying Emmanuel Papadakis's trades and holding each position for 2 Years would result in 43.08% of your transactions generating a profit, with an average return of +11.34% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NVO Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NVO has received 2 Buy Ratings, 25 Hold Ratings, and 2 Sell Ratings. NVO average Analyst price target in the past 3 months is 171.57.

Each month's total comprises the sum of three months' worth of ratings.

NVO Financial Forecast

NVO Earnings Forecast

Next quarter’s earnings estimate for NVO is zł2.86 with a range of zł2.56 to zł3.34. The previous quarter’s EPS was zł3.56. NVO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 50.49% of the time in the same period. In the last calendar year NVO has Performed in-line its overall industry.

NVO Sales Forecast

Next quarter’s sales forecast for NVO is zł41.93B with a range of zł40.51B to zł43.89B. The previous quarter’s sales results were zł45.21B. NVO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 63.25% of the time in the same period. In the last calendar year NVO has Performed in-line its overall industry.

NVO Stock Forecast FAQ

What is PL:NVO’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk’s 12-month average price target is 171.57.

What is PL:NVO’s upside potential, based on the analysts’ average price target?

Novo Nordisk has 1.70% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novo Nordisk a Buy, Sell or Hold?

Novo Nordisk has a consensus rating of Hold, which is based on 1 buy ratings, 11 hold ratings and 2 sell ratings.

What is Novo Nordisk’s share price target?

The average share price target for Novo Nordisk is 171.57. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is zł201.88 ,and the lowest forecast is zł115.36. The average share price target represents 1.70% Increase from the current price of zł168.7.

What do analysts say about Novo Nordisk?

Novo Nordisk’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Novo Nordisk?

To buy shares of PL:NVO, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Novo Nordisk (NVO) Stock Forecast & Price Target

NVO Analyst Ratings

NVO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

NVO Analyst Recommendation Trends

NVO Financial Forecast

NVO Earnings Forecast

NVO Sales Forecast

NVO Stock Forecast FAQ

Detailed List of Analyst Forecasts